RECRUITINGOBSERVATIONAL
French Hypertrophic Cardiomyopathy Observatory
About This Trial
Hypertrophic cardiomyopathy (Hypertrophic CardioMyopathy=HCM) remains a poorly understood disease with an assumption insufficiently codified. There is no data available in France on the profile of patients, diagnostic methods and assessment and therapeutic use. The purpose of this study is to establish a monitoring of patients with HCM (sarcomere of origin or not) in France (diagnosis, treatment)
Who May Be Eligible (Plain English)
Who May Qualify:
- Age ≥ 15 years old
- Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
Who Should NOT Join This Trial:
- Expressed refusal to participate in the study
- Significant aortic stenosis (\<1 cm ²)
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Age ≥ 15 years old
* Patient with HCM defined by an ultrasound thickness of the left ventricle ≥ 13 mm if familial or ≥ 15 mm if sporadic
Exclusion Criteria:
* Expressed refusal to participate in the study
* Significant aortic stenosis (\<1 cm ²)
Locations (1)
European Georges Pompidou Hospital
Paris, France